Company / Cash & Equivalents
Oruka Therapeutics, Inc. Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$61.6M
FY2024
5-year range
$37.4M / $61.6M
FY2020-FY2024
Trend
+64.5%
vs FY2023
Sector context
#172 of 207
Health Care
What the data says
Oruka Therapeutics, Inc.'s cash & equivalents of $62M is lower than 83% of companies in the Health Care sector (FY2024). Cash & Equivalents returned to growth in FY2024 after 2 years of decline, reaching $62M.
Based on SEC 10-K filings.
$62M in FY2024 with a 5-year CAGR of +49.1%.
Improved from $42M to $62M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +4.9%
- 5-Year CAGR
- +49.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 207This company $61.6M Sector average $669.5M
▼
-90.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +49.1%, indicating consistent growth.
- In FY2024, cash & equivalents increased 64.5% year-over-year.
- Ranks #172 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $61.6M | +64.5% |
| FY2023 | $37.4M | -11.8% |
| FY2022 | $42.4M | -20.5% |
| FY2021 | $53.4M | +8.7% |
| FY2020 | $49.1M | +486.8% |
| FY2019 | $8.4M | -3.9% |
| FY2018 | $8.7M | +17.6% |
| FY2017 | $7.4M | -80.9% |
| FY2016 | $38.8M | +152.7% |
| FY2015 | $15.4M | -8.4% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026